- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00375427
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
A Prospective, Randomized, Multi-center Comparative 2-arm Trial of Efficacy and Safety of Zoledronic Acid (Every 3-months vs. Every 4 Weeks) Beyond Approximately 1 Year of Treatment With Zoledronic Acid in Patients With Bone Lesions From Breast Cancer
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Forlì, Italia
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
- Female patients ≥ 18 years of age.
- Written informed consent given.
- Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed.
- Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2 .
- Life expectancy ≥ 1 year.
Exclusion criteria:
- More than 3 months since last infusion of Zoledronic Acid (Zometa®).
- Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry.
- Serum creatinine > 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85
- Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L).
- Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
- Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).
- Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide).
- History of non-compliance to medical regimens or potential unreliable behavior.
- Known sensitivity to study drug(s) or class of study drug(s).
- Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
- Use of any other investigational agent in the last 30 days.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Every 3 months
Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months.
The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Randomized patients will receive a maximum of 4 infusions in this group.
|
Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion.
The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Otros nombres:
|
Experimental: Every 4 weeks
Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks.
The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Patients randomized to this group will receive up to 12 infusions.
|
Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion.
The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Annual Overall Skeletal Morbidity Rate (SMR)
Periodo de tiempo: 12 months
|
The SMR was computed by summing all Skeletal Related Event(s) (SREs)which occurred during the observation period and dividing it by the ratio "days of observation period / 365.25", for each participant. SRE was defined as: pathologic bone fracture, spinal cord compression, surgery to bone both curative and prophylactic, radiation therapy to bone, or hypercalcemia of malignancy. SMR (years) = 365.25 x SMR(days) where SMR (days) = total number of SREs / total SRE risk period (days). Risk period for SMR was computed as the days from randomization date to the date of last visit. |
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Participants Experiencing Skeletal Related Event(s) (SREs)
Periodo de tiempo: 12 month
|
Skeletal Related Events (SREs) are defined as a:
|
12 month
|
Annual Incidence of Any Skeletal Related Events (SREs)
Periodo de tiempo: 12 months
|
Skeletal Related Events (SREs) are defined as a:
|
12 months
|
Median Time to First Skeletal Related Event(s) (SRE)
Periodo de tiempo: 12 month
|
Median Time to first skeletal related event (SRE) is defined as the time from randomization to the date of first occurrence of any SRE which includes at least one of the following: radiation therapy to bone, pathologic bone fracture, spinal cord compression, surgery to bone, and hypercalcemia of malignancy (HCM).
Due to the few numbers of SRE, Kaplan-Meier estimate never reaches a failure probability >=25%; so median time, 25th and 75th percentiles are not determined.For this reason only the estimated percentage of patient SRE free are reported at each time point.
|
12 month
|
Percentage of Participants Skeletal Related Event (SRE) Free
Periodo de tiempo: 12 months
|
Percentage of participants SRE free is defined as the Kaplan-Meier estimate of participants free of any Skeletal Related Events(SRE) at each time point. Skeletal Related Events (SREs) are:
|
12 months
|
Composite Bone Pain Score According to the Brief Pain Inventory (BPI) Questionnaire
Periodo de tiempo: At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Bone pain was assessed by means of a pain score obtained using the Brief Pain Inventory (BPI) questionnaire.
The BPI can produce three pain scores: worst pain, a composite pain score, and a pain interference score.
The composite pain score, which is the average of questions 3, 4, 5 and 6 of the questionnaire was used in this study.
Pain was rated on a scale of 0 (no pain) to 10 (pain as bad as you can imagine).
The outcome is given as the median score for participants at baseline, and 3, 6, 9 and 12 months of treatment
|
At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Evaluation of Pain According to Verbal Rating Scale (VRS) Based on Median Score Value
Periodo de tiempo: At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Pain intensity at rest and on movement is rated by the patient by means of a validated 6-point Verbal Rating Scale (VRS) and refers to the pain which occurred during the last week before the assessment.
Median score value is the median of all the observed scores (none=0, very mild=1, mild=2, moderate=3, severe=5 and very severe=6) at each time point.
|
At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Use Of Analgesic Medications According to the Analgesic Score Scale
Periodo de tiempo: At Baseline, Month 3, Month 6, Month 9 and Month 12
|
The analgesic score used for this study is modified from the Radiation Therapy Oncology Group (RTOG) analgesic score scale. The scale represents type of medication administered from 0 to 4 where: 0 = None
|
At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Assessment of the Eastern Cooperative Oncology Group (ECOG) Performance Score
Periodo de tiempo: At Baseline, Month 3, Month 6, Month 9 and Month 12
|
ECOG Performance Score has 4 grades.
0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities.
Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care.
Totally confined to bed/chair.
Outcome is given as median score for participants at Baseline and 3, 6 , 9 and 12 months of treatment
|
At Baseline, Month 3, Month 6, Month 9 and Month 12
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CZOL446EIT14
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Zoledronic acid
-
Sun Yat-sen UniversityTerminado
-
Centre Hospitalier Universitaire de NiceTerminadoMiocardiopatías diabéticasFrancia
-
University of IowaGlaxoSmithKlineTerminadoEnfermedad cardiovascularEstados Unidos
-
Merck Sharp & Dohme LLCTerminado
-
Merck Sharp & Dohme LLCTerminadoSAHA oral (ácido suberoilanilida hidroxámico) en el linfoma cutáneo avanzado de células T (0683-001)Micosis Fungoide | Síndrome de Sézary | Linfoma cutáneo de células T
-
Merck Sharp & Dohme LLCTerminado
-
Merck Sharp & Dohme LLCTerminado
-
PfizerTerminado
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.TerminadoReceptor de estrógeno negativo | HER2/Neu Negativo | Receptor de progesterona negativo | Cáncer de mama triple negativo | Cáncer de mama anatómico en estadio IV AJCCEstados Unidos